| Literature DB >> 15109534 |
Francis J Giles1, Jorge E Cortes, Hagop M Kantarjian, Susan M O'Brien, Elihu Estey, Miloslav Beran.
Abstract
As fludarabine, topotecan and cytarabine (ara-C) are effective in acute myeloid leukemia (AML), a pilot study of these three agents combined (FTA) was conducted. FTA consisted of topotecan 1.25 mg/m2 by CIV days 1-5, fludarabine 15 mg/m2 and ara-C 0.5 g/m2 IV, BID, on days 2-6. Seventeen patients (6 primary resistant, 11 relapsed) with AML received 33 courses of FTA. Six patients (35%) achieved complete remission. Seven patients (41%) developed grade 3 or 4 diarrhea. FTA was effective and warrants further study in patients with refractory AML.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15109534 DOI： 10.1016/j.leukres.2003.08.013
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156